Table 1.

Selected Registered Clinical Trials^* Addressing Mineral and Bone Disorder (MBD) and Cardiovascular Disease (CVD) or Personalized MBD Therapy

Example Ongoing Studies of MBD and CVD Registered on Clinicaltrials.gov
NCT #	MBD/CVD	Population	ClinicalTrials.gov Status	Intervention	Duration	CVD Outcome
03234361	Inorganic phosphorus and BP	Healthy individuals	Ongoing	Sodium phosphate vs. sodium chloride	4 weeks	24 hour ABPM
02837328	Magnesium and arrhythmia	Healthy individuals	Recruitment completed	Magnesium citrate vs. placebo	4 weeks	Premature atrial contractions
02620449	Dietary phosphorus and vascular function	Healthy individuals	Ongoing	Diet low in additive- based phosphorus	10 weeks	Pulse wave velocity; Flow- mediated dilatation-
02545426	Dialysate calcium and myocardial stunning	Patients with ESRD on hemodialysis	Recruitment completed	Dialysate calcium 2.5 vs. 3.5 mEq/L	1 week	Echocardiographic strain
02224144	1,25-D and vascular calcification	Kidney transplant recipients	Active, not recruiting	Calcitriol vs. placebo added to vitamin D3	12 months	Lower extremity vascular calcifications
02542319	Magnesium supplementation and vascular calcification	Patients with CKD	Recruiting	Oral magnesium supplementation	12 months	Coronary artery calcification score
02087683	Vitamin D and cardiac remodeling	Patients with heart failure and vitamin D deficiency	Recruiting	Vitamin D supplementation	12 months	Change in myocardial function and structure
01528800 02870829 01742273	Vitamin K and vascular calcification	Patients with ESRD on hemodialysis	Active, not recruiting/ Recruiting	Vitamin K	12– 18month s	Coronary artery calcification
02258074	Phosphorus lowering and cardiac remodeling	Patients with CKD	Active, not recruiting	Factorial: Lanthanum carbonate vs. placebo, nicotinamide vs. placebo	12 months	Left ventricular mass and geometry
Example Ongoing Studies of Personalized MBD Therapy Registered on Clinicaltrials.gov
NCT #	MBD Theme	Population	ClinicalTrials.gov Status	Intervention/Question	Duration	Personalized Outcome
02925195	Vitamin D response	General population	Ongoing	Cholecalciferol; Effect modification by clinical traits and genes	16 weeks	Vitamin D concentrations; PTH
02802449	Vitamin D in African Americans	African Americans	Active, not recruiting	Vitamin D supplementation; Interaction with genetic and biologic factors	8 weeks	PTH; inflammatory markers
03134417	Vitamin D and magnesium	Individuals with obesity	Recruiting	Vitamin D vs. Vitamin D plus magnesium vs. placebo; Magnesium as critical co-factor	12 weeks	PTH; lipids; BP
02572960	Vitamin D, PTH and RAAS interaction	Vitamin D deficiency and secondary hyperparathyroidism	Recruiting	Factorial: Valsartan vs. placebo, Vitamin D3 vs. placebo; Interaction of Vitamin D and RAAS	12 weeks	Aldosterone; PTH; vascular measures

^#NCT , ClinicTrials.gov identifier; BP, blood pressure; ABPM, ambulatory blood pressure monitoring; ESRD, end-stage renal disease; 1,25-D, 1,25-dihydroxyvitamin D; CKD, chronic kidney disease; PTH, parathyroid hormone; RAAS, renin angiotensin aldosterone system

^*Studies of MBD were identified by systematically searching ClinicalTrials.gov using keywords including “phosphorus”, “calcium”, “parathyroid”, “vitamin D”, “fibroblast growth factor 23”, “magnesium”, and “mineral and bone disorder”. Subsequently, example interventional studies were selected from among those in active, ongoing or recruiting status.